CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 13 of the 34 sources its claims cite were checked for support.

Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study

Open access
Groot, Peter C., van Os, Jim · 2021 · Therapeutic Advances in Psychopharmacology

Abstract

Background: Tapering strips facilitate antidepressant discontinuation, allowing for personalised titration of discontinuation to the intensity of withdrawal. A tapering strip consists of antidepressant or other medication, packaged in a 28-day roll of daily pouches, each with the same or slightly lower dose than the one before. Previous studies demonstrated 70% real-world effectiveness of tapering strips. Here, we present a third, questionnaire-based retrospective cohort study in a large sample. Methods: Patients whose doctor had prescribed tapering strips between October 2015 and December 2018 were sent a questionnaire for participation after completion of tapering between December 2015 and January 2020. Of 1240 individuals who returned a questionnaire (response rate: 59%), 987 (80%) used an antidepressant, of whom 824 (83%) had wished to discontinue their antidepressant. Results: The sample was demographically representative of antidepressant users in the Netherlands. Less than 40% of participants had heard of tapering strips through their clinicians – Internet was the most frequent source. Of the 824 individuals, 341 (41%) had used strips for tapering venlafaxine, 206 (25%) for paroxetine and 277 (34%) for other antidepressants. Median duration of antidepressant use was 5–10 years, and most (71%) had tried to come off without tapering strips at least once. Most patients (72%) were able to discontinue their antidepressant, using a median of two strips to taper over a median period of 56 days. Females and individuals with (1) more severe experience of withdrawal during the use of tapering strips, (2) more years of use of antidepressant medication and (3) more previous attempts at discontinuation were less likely to be able to discontinue their antidepressant medication with tapering strips. Conclusion: The results of this study validate, for the third time, the observation that tapering strips can address the problem of antidepressant withdrawal symptoms in individuals attempting to discontinue antidepressants.

Overview

CoChat Summary

TL;DR

In a retrospective questionnaire cohort of 824 Dutch antidepressant users prescribed tapering strips, 72% reported discontinuing their antidepressant, using a median of two strips over a median of 56 days. Longer antidepressant use, female sex, more withdrawal during tapering, and antidepressants other than venlafaxine were associated with lower odds of successful tapering.

Key findings

  • Successful tapering was reported by 72% (568/824; 31 missing values); participants used a median of 2 tapering strips over a median of 56 days.
  • The sample was demographically representative of adult antidepressant users in the Netherlands (mean age 49.5 years; 75% female; NEMESIS-2 comparison: mean age 49.5 years, 69% female). Tapering was for venlafaxine in 41%, paroxetine in 25%, and other antidepressants in 34%; 71% had previously tried to come off without tapering strips.
  • In univariable logistic regression, lower odds of successful tapering were associated with female sex (OR = 0.672, 95% CI: 0.462–0.978), longer duration of use (OR linear trend = 0.694, 95% CI: 0.603–0.798), more previous attempts (OR linear trend = 0.824, 95% CI: 0.725–0.937), more withdrawal with tapering strips (OR linear trend = 0.825, 95% CI: 0.733–0.928), paroxetine versus venlafaxine (OR = 0.496, 95% CI: 0.335–0.737), and other antidepressant versus venlafaxine (OR = 0.611, 95% CI: 0.423–0.886).
  • In multivariable regression, associations were retained for female sex (OR = 0.502, 95% CI: 0.284–0.886), duration of use (OR linear trend = 0.618, 95% CI: 0.494–0.774), withdrawal with tapering strips (OR = 0.851, 95% CI: 0.751–0.963), and other antidepressant versus venlafaxine (OR = 0.508, 95% CI: 0.305–0.846); previous attempts and paroxetine were not retained.

Methods

  • Retrospective questionnaire-based cohort: patients prescribed tapering strips between October 2015 and December 2018 were invited after completing tapering between December 2015 and January 2020; 1240 returned questionnaires (response rate 59%), 987 (80%) used an antidepressant, and 824 (83%) wished to discontinue and were included.
  • Variables included age, sex, medication type and duration, previous discontinuation attempts, withdrawal severity on 1–7 Likert scales, tapering quality on 1–7 Likert scales, and whether the individual tapered off completely; the main outcome was “successful tapering” (off medication after completion of tapering strips).
  • Univariable and multivariable logistic regression yielded odds ratios and 95% confidence intervals; age and sex distribution were compared with the NEMESIS-2 sample, and no large or significant interactions with antidepressant categories were found.

Limitations

  • Stated: the sample was largely selected by referring physicians for unsuccessful previous tapering and chronic antidepressant use, so the 72% success rate applies to a group considered most at risk of severe withdrawal; around 60% responded, with possible selective non-response bias.
  • Stated: the brief quality-assurance questionnaire limited more precise assessment of variables such as relapse type, prescriber support, total tapering trajectory length, and current symptoms; withdrawal assessment was subjective, and recall of previous withdrawal may have been influenced by the more recent tapering-strip experience.
  • Evident: this was an uncontrolled, retrospective, self-report cohort without a randomized or usual-care comparison arm, so causal conclusions about tapering strips cannot be drawn; the paper also notes no follow-up after tapering in the current study, only the tapering period and outcome.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253211039327

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Comparison of tapering trajectories without tapering strips (left) and with tapering strips (right), on outcomes of tapering and severity of withdrawal.
Figure 1. Comparison of tapering trajectories without tapering strips (left) and with tapering strips (right), on outcomes of tapering and severity of withdrawal.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 15 Not checked · 47 Own results and interpretations

29 more claims

Create a free account to see all 73 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Van Leeuwen E, 2021, Cochrane Database Syst Rev, 4

Cited by

See all 38

Metadata

Authors
Groot, P. C., & van Os, J.
Affiliations
  • University Medical Center Utrecht (NL)
  • Department of Psychiatry, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands
Venue
Therapeutic Advances in Psychopharmacology
Published
2021-01
Volume
11
Pages
20451253211039327-20451253211039327
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W3197897999
Cited by
38
References
28
Citations by year
2026: 6 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 4
FWCI
3.36
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
antidepressant discontinuation, antidepressant withdrawal symptoms, venlafaxine, paroxetine, patient-reported outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. https://app.cochat.ai/papers/10.1177/20451253211039327
The paper
Groot, P. C., & van Os, J. (2021). Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253211039327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.